Related Experiment Video

Updated: Jun 6, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Cell treatment after acute myocardial infarction prevents early decline in circulating IGF-1

Haakon K Grøgaard1, Ingebjørg Seljeflot, Ketil Lunde

  • 1Institute for Experimental Medical Research, Oslo University Hospital, Ullevål, University of Oslo, Oslo, Norway. h.k.grogaard@medisin.uio.no

Scandinavian Cardiovascular Journal : SCJ
|November 18, 2010
PubMed

Insights

Bone marrow cell therapy after myocardial infarction impacts insulin-like growth factor-1 (IGF-1) levels. Higher IGF-1 concentrations were associated with improved left ventricular ejection fraction in patients.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Molecular Cardiology

Background:

  • Acute myocardial infarction (AMI) can lead to impaired left ventricular (LV) function.
  • Intracoronary cell transplantation is being investigated as a therapeutic strategy post-AMI.
  • The impact of cell therapy on circulating growth factors and LV function requires elucidation.

Purpose of the Study:

  • To investigate the effect of intracoronary autologous bone marrow cell transplantation on circulating growth factors after AMI.
  • To determine the relationship between changes in growth factors and left ventricular function.

Main Methods:

  • The ASTAMI study randomized patients to receive either cell treatment or a control.
  • Circulating levels of insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), stromal derived factor-1-alpha (SDF-1α), and transforming growth factor beta (TGF-β) were measured.
  • Left ventricular ejection fraction (LVEF) was assessed using single photon emission computed tomography at six months.

Main Results:

  • A significant difference in IGF-1 change from baseline to three months was observed between the cell treatment and control groups (p = 0.024).
  • A weak but significant correlation (r = 0.24, p = 0.02) was found between LVEF and averaged IGF-1 concentrations.
  • Patients with IGF-1 levels above the median demonstrated a significantly higher LVEF (52.3%) compared to those below the median (46.4%, p = 0.017).

Conclusions:

  • Intracoronary bone marrow cell treatment following myocardial infarction appears to attenuate the reduction in circulating IGF-1.
  • IGF-1 levels over time showed a weak but significant correlation with left ventricular ejection fraction.
Abstract

More Related Videos

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...